Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046332 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00046332 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants.
The verdict
NCT00046332, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.
Interventions
- DRUG GW810781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046332
The ClinicalTrials.gov registry entry for NCT00046332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW810781 is the first listed.
NCT00046332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046332 about?
NCT00046332 is a clinical study titled "A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients". This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.
What is the current status of trial NCT00046332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2002-06. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00046332?
The interventions under investigation include: GW810781 (DRUG).
Who is sponsoring clinical trial NCT00046332?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.